Improvement of outcomes of an escalated high‐dose methotrexate-based regimen for patients with newly diagnosed primary central nervous system lymphoma: a real-world cohort study

Abstract

There is a correlation of treatment response and clinical outcomes between the dosage of MTX in initial induction therapy in newly diagnosed PCNSL. MTX dose of 8 g/m² provided a higher CR rate and PFS benefits with acceptable adverse effects.